New pill aims to slow lung scarring in rare disease
NCT ID NCT05139719
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This study tests an experimental drug called HEC585 in people with progressive fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and breathing gets worse over time. About 110 adults will receive either a low dose, high dose, or a placebo for at least 24 weeks, with an option to continue up to 96 weeks. The main goal is to see if the drug can slow the decline in lung function compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE (PF-ILD) / PROGRESSIVE PULMONARY FIBROSIS (PPF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.